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Abstract
Background: Africa continues to bear a disproportionate share of the global HIV/AIDS, tuberculosis (TB) and malaria 
burden. The development and distribution of safe, effective and affordable vaccines is critical to reduce these 
epidemics. However, conducting HIV/AIDS, TB, and/or malaria vaccine trials simultaneously in developing countries, or 
in populations affected by all three diseases, is likely to result in numerous ethical challenges.
Methods: In order to explore convergent ethical issues in HIV/AIDS, TB and malaria vaccine trials in Africa, the Ethics, 
Law and Human Rights Collaborating Centre of the WHO/UNAIDS African AIDS Vaccine Programme hosted a 
consultation on the Convergent Ethical Issues in HIV/AIDS, TB and Malaria Vaccine Trials in Africa in Durban, South Africa on 
the 10-11 February 2009.
Results: Key cross cutting ethical issues were prioritized during the consultation as community engagement; ancillary 
care obligations; care and treatment; informed consent; and resource sharing.
Conclusion: The consultation revealed that while there have been few attempts to find convergence on ethical issues 
between HIV/AIDS, TB and malaria vaccine trial fields to date, there is much common ground and scope for 
convergence work between stakeholders in the three fields.
Background
Africa continues to bear a disproportionate share of the
global burden of HIV, TB and malaria.  There are 22 mil-
lion people living with HIV in sub-Saharan Africa, 67% of
the 33 million people living with HIV globally [1]. An
estimated 9.27 million new cases of TB [2] and 1.7 million
deaths from TB [3] occurred globally in 2007. Thirteen of
the 15 countries with the highest estimated TB incidence
rates are in Africa, a result of high rates of HIV co-infec-
tion [2]. In 2006, there were an estimated 247 million epi-
sodes of malaria and an estimated 881 000 malaria deaths
[4]. Eighty-six percent (212 million) of these malaria epi-
sodes and 91% (801 000) of malaria deaths in 2006
occurred in Africa (Ibid.). Malaria and TB complicate the
effective control of HIV, due to their shared risk factors,
geographic overlap and co-infection, particularly in sub-
Saharan Africa. TB is a leading cause of death among
people living with HIV/AIDS in Africa [5]. Only 1% of
people living with HIV/AIDS are reported to have been
screened for TB, of which more than 25% have TB [6].
HIV also increases the risk of malaria infection and the
development of clinical malaria, while malaria has been
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shown to induce HIV-1 replication and increase HIV
viral load [7].
Despite the variety of prevention, treatment and care
initiatives in existence, significant challenges in curbing
these diseases remain. The development and distribution
of vaccines that are safe, effective and affordable is critical
to reduce disease and mortality from HIV/AIDS, TB, and
malaria. The geographic overlap, shared risk factors and
possibility for co-infection between HIV/AIDS, TB, and
malaria mean that these diseases can no longer be consid-
ered in isolation. International cooperation and the devel-
opment and testing of multiple vaccines simultaneously,
are required to curb these epidemics.
The last few years have seen significant progress in the
development of vaccines against HIV/AIDS, TB, and
malaria. Despite several setbacks, the search for a safe
and effective HIV/AIDS vaccine continues. There are
presently HIV/AIDS vaccine trials being conducted in
four African countries namely Uganda, Kenya, Tanzania
and South Africa [8]. Proof-of-concept of vaccine-
induced protection from malaria infection and disease
has recently been demonstrated in African children and
several candidate malaria vaccines are in early clinical tri-
als [9]. In Africa, malaria vaccine clinical trials are ongo-
ing in Mozambique, Tanzania, Gabon, Ghana, Kenya, the
Gambia, Burkina Faso and Mali (Ibid.). While a TB vac-
cine, Bacillus Calmette-Guérin (BCG), is available, it pro-
vides approximately 80% protection against TB
meningitis and miliary TB in infancy and in young chil-
dren but provides only variable protection against lung
disease, at all ages, creating an urgent need for new candi-
date vaccines [10]. In Africa, TB vaccine trials are being
conducted in South Africa and the Gambia (Ibid.), with
site development taking place in Kenya, Uganda, Mozam-
bique and Tanzania.
Conducting vaccine trials in developing countries is
ethically complex and requires careful consideration of
several key issues [11]. HIV/AIDS, TB, and malaria vac-
cine trials each present unique ethical challenges. HIV/
AIDS vaccine trial participants, for example, may experi-
ence discrimination accorded to individuals perceived to
be at high risk of HIV/AIDS or as a result of false sero-
positivity on conventional HIV testing methods [12]. In
Malaria vaccine research the ethics of testing transmis-
sion-blocking vaccines that do not protect vaccinees from
infection or disease but prevent infection of others, needs
careful consideration [13]. In TB vaccine research, the
use of placebo controlled trials may be considered uneth-
ical as standard BCG vaccines (although not reliably effi-
cacious for TB prevention) are widely used and as such
could, depending on the characteristics of the study pop-
ulation, be provided to control groups [14]. In addition to
such challenges, conducting HIV/AIDS, TB, and/or
malaria vaccine trials simultaneously in developing coun-
tries, or in populations affected by all three diseases, is
likely to result in numerous other ethical challenges.
Methods
In order to explore convergent ethical issues in HIV/
AIDS, TB and malaria vaccine trials in Africa, the Ethics,
Law and Human Rights Collaborating Centre of the
WHO/UNAIDS African AIDS Vaccine Programme
hosted a consultation on the Convergent Ethical Issues in
HIV/AIDS, TB and Malaria Vaccine Trials in Africa in
Durban, South Africa on the 10-11 February 2009. This
meeting aimed to bring together key stakeholders from
HIV/AIDS, TB, and malaria vaccine initiatives to explore
the convergent ethical issues in the three fields and to
promote and impact cooperation, networking and
resource sharing in Africa. Participants included spon-
sors, investigators, research ethics committee members
and community representatives working in the fields of
HIV/AIDS, TB and malaria vaccine research. This paper
outlines the key convergent ethical issues and recommen-
dations identified during the consultation.
Results and discussion
Ethical issues in HIV, TB and Malaria vaccine trials
Using an informal ranking exercise, the key cross cutting
ethical issues in HIV/AIDS, TB, and malaria vaccine
research in Africa, were roughly prioritized by stakehold-
ers in the consultation as follows,: 1) Community engage-
m e n t ;  2 )  A n c i l l a r y  c a r e  o b l i g a t i o n s ;  3 )  C a r e  a n d
treatment; 4) Informed consent; 5) Resource sharing.
These are detailed below, with recommendations for
each.
1. Community Engagement
Identified Issues Community engagement approaches
appear to be better developed in HIV/AIDS research than
in research relating to TB and malaria. HIV/AIDS
research typically includes broad community education
campaigns (which are not specific to the research study,
but are about HIV/AIDS more generally) and community
consultation regarding specific studies. Conversely, TB
related trials have, in general, not included such commu-
nity involvement and preparation for research. This
m igh t be  a r gu ed t o be  a r es ul t  o f  t he  glo bal  advoca cy
around HIV/AIDS (and the fact that unlike malaria and
TB, HIV/AIDS has had a marked impact on the devel-
oped world). HIV/AIDS advocacy in North America
changed human rights globally. HIV/AIDS became more
than a health-related issue and is now also a political
issue. Despite this difference, stakeholders agreed that
relationships with communities are an important ethical
concern for all three fields and that community engage-
ment needs to move beyond the tokenistic involvement
of the community and towards more power sharing rela-
tionships. Community engagement is a critical compo-Mamotte et al. BMC Medical Ethics 2010, 11:3
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nent in clarifying reasonable expectations regarding
study results (outcomes and access to products post-trial)
and care, for managing issues around the therapeutic
misconception and for ensuring that procedures are cul-
turally sensitive. Community engagement is also increas-
ingly desired and required when considering at what
stage in trial planning to involve communities and how
best to do so.
Recommendations It is recommended that a science of
community engagement be encouraged [15], where
stakeholders place as much emphasis on researching and
engaging with the community as they do on conducting
trials and that negotiation skills be imparted to commu-
nities so that they can participate as active partners in the
trial planning and process. It is also recommended that
the UNAIDS Ethics Guidance [16] and Good Participa-
tory Practice (GPP) [17] documents, developed for pre-
ventive HIV/AIDS research, be adapted and used by
investigators in malaria and TB prevention initiatives.
2. Ancillary Care Obligations
Identified Issues Careful advanced planning on which
ancillary diseases will be treated is essential [18-20].
Ancillary care is defined as care provided to clinical trial
participants which goes beyond the requirements of sci-
entific validity, safety, keeping promises, or rectifying
injuries [18]. Investigators may perform ancillary care
procedures if they are minor and will not impact on the
study protocol. The provision of ancillary care is poten-
tially problematic. For example, in cases where the ancil-
lary care results in harm, what liability is there on the
investigators or sponsors and what implications could the
provision of ancillary care, even if protocol specific, have
for study and investigator insurance? The provision of
ancillary care may complicate the relationship between
investigators and study participants. Participants may
come to view the research relationship as therapeutic and
may come to trust investigators to a degree where they
unquestioningly accept investigative procedures [20]. The
provision of ancillary care and the potential blurring of
the investigative relationship with a therapeutic one may
potentially exacerbate the therapeutic misconception
[21]. This could be a particular concern for HIV/AIDS
vaccine trials where the therapeutic misconception could
potentially lead to behavioural disinhibition in some par-
ticipants [22]. Furthermore, the provision of ancillary
care in one study may lead to raised expectations of care
in future studies.
Recommendations It is recommended that the provision
of ancillary care be carefully considered during protocol
development, in consultation with host communities,
and that responsibility for investigative and ancillary care
procedures is effective, clearly differentiated and per-
formed by designated or different members of the trial
staff. It is also recommended that a priori partnerships be
forged and formalized between local health service pro-
viders and researchers to develop a referral system for
ancillary care prior to trial initiation so that participants
can be referred for ancillary care, when appropriate.
3. Care and Treatment
Identified Issues Defining the standard of care and
treatment to be provided when a participant becomes
infected with the pathogen under study is a contentious
issue. While TB and malaria are curable and treatments
are relatively inexpensive and readily available, HIV/
AIDS remains incurable and life-long treatment is
required. Standards of care and treatment, particularly
for HIV/AIDS, are usually much higher in sponsor coun-
tries (Europe and North America) and sponsors may
require this higher standard in developing country set-
tings when it is not the norm for the local population.
This issue is a particular concern for multi-centre studies
where the standard of care and treatment may vary across
centres, or across participants and non-participants
within a host country . Regardless of which standard is
implemented, research sites generally provide better care
than that which is provided by the health systems in the
h os t  c o u n t ry .  S u s t a i n a b i l i t y  o f  t h is  'h i g h e r '  s t a n da r d  o f
care and treatment beyond the duration of the study is a
challenge faced by many investigators.
Recommendations Clear boundaries regarding care and
treatment obligations need to be delineated. In contexts
where referral systems are well-developed and investiga-
tors can refer participants, follow-up is crucial as the eth-
ical responsibility to participants does not end once
referrals are made. Complex decisions on how care and
treatment obligations should be met should be trial spe-
cific and made through an open and participatory process
before a trial begins [16,23]. The type, range and duration
of care and treatment provided, as well as who will
finance and implement it, should also be decided on in
advance (Ibid.).
4. Informed Consent
Identified Issues Factors such as poor health delivery
systems, poverty, the therapeutic misconception and illit-
eracy may hinder the process of obtaining truly informed
consent. In malaria and TB vaccine research, where tar-
get populations are often children, extra care and effort
are needed on the part of research teams when obtaining
proxy consent from parents/guardians, especially in cases
where the parents may themselves be minors. Sponsors
often require long, detailed and overly legalistic consent
forms to be administered. These forms are intimidating
and challenging to administer due to low levels of literacy
among the majority of volunteers. As such, understand-
ing may be limited. Therefore, local investigators argue
for short, simplified versions of consent forms. Changing
consent form templates involves significant power
dynamics between sites and sponsors, and some sponsorsMamotte et al. BMC Medical Ethics 2010, 11:3
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may be unwilling to relinquish this. The debate about
length, detail and usefulness of consent forms may be
seen as a function of over-regulation of the clinical trials
industry. Studies are often not approved if they do not
include lengthy consent forms, regardless of their appro-
priateness. This may be reflective of assumptions that
mere compliance with regulations regarding what to
include in consent forms is equal to meeting certain ethi-
cal standards, which is not necessarily the case.
Recommendations Sharing of simple and effective con-
sent form templates and procedures across disease areas
is recommended [24] as is the need to focus on the 'pro-
cess' of consent and supplementary consent materials,
rather than only on the actual form, in order to make
meaningful consent more possible. It is also recom-
mended that comprehension tests be administered to
participants prior to and during participation in clinical
trials to ensure that they understand important trial con-
cepts. Community Advisory Groups should also be edu-
cated on clinical trial procedures so that they can review
the contents of the consent forms and materials [17].
5. Resource Sharing
Identified Issues Collaborative relationships between
researchers and research centres, working within, and
across, each of the disease entities is critical in promoting
infrastructural and capacity development in developing
countries, and in responding to ethical challenges. Work-
ing in pathogen-specific silos is an artifact, as TB, HIV/
AIDS and malaria are related and are often co-morbid,
and communities may want attention paid to the spec-
trum of diseases affecting them. Attempts to diversify
across fields should acknowledge that working in silos
does tend to serve donor priorities and thus researchers'
personal career interests, particularly in light of competi-
tion for funding. Sharing of resources and capacity across
disease areas may however help to avoid wasting capacity,
(e.g., clinical trial capacity, laboratory capacity) which has
been established in research teams, between trials, and
when candidate products are unavailable. Potential barri-
ers to resource sharing include institutional separation,
ignorance of each field's history and unique challenges,
constrained resources and different timelines. Potential
enablers include identifying common platforms of issues
and developing models and tools that can serve more
than one initiative. The principal advantages are the max-
imisation of finite resources and energies, and the promo-
tion and retention of local capacity.
Recommendations Given the limited resources and
capacity in Africa, it is recommended that where capacity
has been developed, and where sophisticated infrastruc-
ture has been put in place, within a disease entity, this
s h o u l d  b e  s h a r e d  w i t h i n  a n d  a c r o s s  d i s e a s e  e n t i t i e s  i n
order to further the objective of addressing health and
development at a broader level. This would include the
sharing of training resources (around ethics, research
conduct and community research literacy) across disease
entities. This would also enable the retention of scarce
skills and reduce 'brain drain' from the developing world.
Conclusion
The consultation revealed that while there have been few
attempts to find convergence on ethical issues between
HIV/AIDS, TB and malaria vaccine trial fields to date,
there is much common ground and scope for conver-
gence work between stakeholders in the three fields.
Based on recommendations made during the consulta-
tion, a steering committee has been established and pos-
sible funding sources have been identified to move the
convergence agenda forward. Additional activities rec-
ommended to move the convergence agenda forward
include: An empirical study of how key stakeholders in
HIV/AIDS, TB and malaria vaccine trials would prioritise
convergent ethical issues; the documentation of the exis-
tence of disease specific 'silos'; a study of knowledge dif-
ferences and barriers to convergence between the three
fields; and the hosting of a larger forum, with better rep-
resentation from the key stakeholders and decision mak-
ers in the three fields, to debate these issues further.
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